Extended Data Fig. 1: EPHA2, HER2 and IL13Rα2 are immunotherapy targets in Group 3 medulloblastoma.

a, EPHA2 mRNA expression in human Group 3 medulloblastoma versus normal human adult and fetal cerebellum; b, HER2 expression in human Group 3 medulloblastoma versus normal human adult and fetal cerebellum; and c, IL13Rα2 expression in human Group 3 medulloblastoma versus normal human fetal and adult cerebellum, by expression microarray, two-sided Mann-Whitney U test. mRNA differential expression across human medulloblastoma subtypes versus normal adult and fetal cerebellum control for d, EPHA2; e, HER2; and f, IL13Rα2; as compared by expression microarray, * P < 0.05; **P < 0.005, two-sided Mann-Whitney U-test. g, EPHA2 mRNA expression in human WNT, SHH and Group 4 medulloblastoma subgroups versus normal human adult and fetal cerebellum h, HER2 mRNA expression in human WNT, SHH and Group 4 medulloblastoma subgroups versus normal human adult and fetal cerebellum; and i. IL13Rα2 mRNA expression in human WNT, SHH and Group 4 medulloblastoma subgroups versus normal human adult and fetal cerebellum as compared by expression microarray, two-sided one-way ANOVA with post-hoc Tukey HSD. All boxplot center lines show data median; box limits indicate the 25th and 75th percentiles; lower and upper whiskers extend 1.5 times the interquartile range (IQR) from the 25th and 75th percentiles, respectively. Outliers are represented by individual points. Error bars ± SEM j, H score of EPHA2 IHC (P = 0.6); k, H score of HER2 IHC (P = 0.6); l, H score of IL13Rα2 IHC (P = 0.9 two-sided Mann-Whitney U test) in human paediatric primary and metastases or recurrence for Group 3 medulloblastoma. m, Normal skeletal muscle used for EPHA2 and HER2-negative controls; normal colon used for EPHA2-positive controls; HER2-positive breast cancer used as HER2-positive controls; normal pancreas and testis used for IL13Rα2-negative and positive controls, respectively. Scale bar represents 100 mM, data represents 3 Biological replicates.